

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal TA393; Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia and TA394; Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Companies</u></p> <ul style="list-style-type: none"> • Sanofi (Alirocumab) • Amgen (Evolocumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency • British Cardiac Patients Association • Cardiovascular Care Partnership • Equalities National Council • Genetic Alliance UK • HEART UK • Muslim Council of Britain • Network of Sikh Organisations • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Nursing in Cardiovascular Care • British Cardiovascular Intervention Society • British Cardiovascular Society • British Dietetic Association • British Geriatrics Society • British Heart Foundation • British Inherited Metabolic Disease Group • British Society for Genetic Medicine • National Metabolic Biochemistry Network • Primary Care Cardiovascular Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (fluvastatin, pravastatin, simvastatin) • Actavis (atorvastatin, fluvastatin, pravastatin, simvastatin) • Amneal (pravastatin, simvastatin) • Aptil (fluvastatin, simvastatin) • Arrow (atorvastatin, pravastatin, simvastatin) • Aspire Pharma (atorvastatin, fluvastatin) • AstraZeneca (rosuvastatin) • Aurobindo Pharma (simvastatin) • Bristol Laboratories (simvastatin) • Bristol-Myers Squibb (colestyramine, pravastatin)

<ul style="list-style-type: none"> • Royal Society of Medicine • Society for Cardiological Science & Technology • Society for Endocrinology • Vascular Society for Vascular Technology of Great Britain and Ireland • Society of Vascular Nurses • UK Clinical Pharmacy Association • UK Genetic Testing Network • UK Health Forum <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Corby CCG • NHS England • NHS Erewash CCG • Welsh Government 	<ul style="list-style-type: none"> • Chanelle Medical UK (simvastatin) • Consilient (atorvastatin) • Crescent (pravastatin, simvastatin) • Dexcel-Pharma (atorvastatin, simvastatin) • Discovery Pharmaceuticals (simvastatin) • Dr Reddy's Laboratories (atorvastatin)Hexal (simvastatin) • Kent (simvastatin) • Kiron (simvastatin) • Lupin (simvastatin) • Medley Pharma Ltd (simvastatin) • Medreich (pravastatin, simvastatin) • Merck, Sharp & Dohme (ezetimibe, simvastatin, simvastatin with ezetimibe) • Metwest (simvastatin) • Mylan (benzafibrate, fluvastatin, pravastatin, simvastatin) • Novartis Pharmaceuticals (fluvastatin) • Pfizer (acipimox, atorvastatin, colestipol, gemfibrozil) • Pharmathen (fluvastatin) • Sun Pharmaceuticals (atorvastatin, pravastatin, simvastatin) • Rosemont Pharma (simvastatin) • Sandoz (bezafibrate, fenofibrate, fluvastatin, pravastatin, simvastatin) • Sanofi (colesevelam) • Teva UK (atorvastatin, bezafibrate, colestyramine, fenofibrate, fluvastatin, gemfibrozil, pravastatin, simvastatin) • Tillomed (pravastatin, simvastatin) • simvastatin) • Wockhardt UK (atorvastatin, simvastatin) • Yiling (pravastatin) • Zanza (simvastatin) • Zentiva (atorvastatin, ciprofibrate, fenofibrate, fluvastatin, pravastatin, simvastatin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • Central Cardiac Audit Database • Cochrane Cystic Fibrosis and Genetic Disorders Group • Cochrane Heart Group
---	--

APPENDIX B

	<ul style="list-style-type: none">• Genomics England• MRC Clinical Trials Unit• National Centre for Cardiovascular Preventions and Outcomes• National Institute for Health Research• Society for the Study of Inborn Errors of Metabolism• Wellcome Trust - Cardiovascular Research Initiative <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none">• Public Health England• Public Health Wales
--	---

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.